Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 4.40B | P/E | - | EPS this Y | 109.10% | Ern Qtrly Grth | - |
| Income | -73.52M | Forward P/E | 85.85 | EPS next Y | 350.00% | 50D Avg Chg | -2.00% |
| Sales | 287.61M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 102.00% |
| Dividend | N/A | Price/Book | 8.70 | EPS next 5Y | - | 52W High Chg | -17.00% |
| Recommedations | 2.50 | Quick Ratio | 5.52 | Shares Outstanding | 279.35M | 52W Low Chg | 376.00% |
| Insider Own | 0.32% | ROA | -8.49% | Shares Float | 247.85M | Beta | 1.17 |
| Inst Own | 86.52% | ROE | -19.88% | Shares Shorted/Prior | 20.61M/20.64M | Price | 17.17 |
| Gross Margin | 26.42% | Profit Margin | -25.56% | Avg. Volume | 6,453,858 | Target Price | 25.50 |
| Oper. Margin | 22.88% | Earnings Date | Feb 28 | Volume | 5,319,396 | Change | -5.89% |
About ImmunoGen, Inc.
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Coen Stacy Ann | SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER | Feb 02 | Sell | 29.3 | 4,583 | 134,282 | 73,274 | 02/06/24 |
| Coen Stacy Ann | SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER | Feb 02 | Option | 0 | 14,350 | 77,857 | 02/06/24 | |
| Wingrove Theresa | SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS | Feb 02 | Sell | 29.3 | 12,027 | 352,391 | 21,039 | 02/06/24 |
| Wingrove Theresa | SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS | Feb 02 | Option | 0 | 29,640 | 33,066 | 02/06/24 | |
| Enyedy Mark J | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Feb 02 | Sell | 29.28 | 20,107 | 588,733 | 584,397 | 02/06/24 |
| Enyedy Mark J | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Feb 02 | Option | 0 | 51,234 | 604,504 | 02/06/24 | |
| Lentini Renee | VP & PRIN ACCTG OFFI.. VP & PRIN ACCTG OFFICER | Feb 02 | Sell | 29.3 | 2,631 | 77,088 | 14,723 | 02/06/24 |
| Lentini Renee | VP & PRIN ACCTG OFFI.. VP & PRIN ACCTG OFFICER | Feb 02 | Option | 0 | 8,435 | 17,354 | 02/06/24 | |
| Wingrove Theresa | SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS | Jan 16 | Sell | 29.64 | 187,667 | 5,562,450 | 3,426 | 01/18/24 |
| Wingrove Theresa | SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS | Jan 16 | Option | 5.28 | 187,667 | 990,882 | 191,093 | 01/18/24 |
| Coen Stacy Ann | SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER | Dec 29 | Option | 5.32 | 30,000 | 159,600 | 63,140 | 01/03/24 |
| Lentini Renee | VP & PRIN ACCTG OFFI.. VP & PRIN ACCTG OFFICER | Dec 22 | Sell | 29.74 | 6,548 | 194,738 | 8,452 | 12/27/23 |
| Lentini Renee | VP & PRIN ACCTG OFFI.. VP & PRIN ACCTG OFFICER | Dec 22 | Option | 0 | 15,000 | 15,000 | 12/27/23 | |
| Wingrove Theresa | SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS | Dec 15 | Sell | 29.4 | 117,445 | 3,452,883 | 2,811 | 12/19/23 |
| Wingrove Theresa | SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS | Dec 15 | Option | 4.94 | 117,445 | 580,178 | 120,256 | 12/19/23 |
| Coen Stacy Ann | SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER | Nov 30 | Sell | 29.20 | 3,826 | 111,719 | 33,140 | 12/05/23 |
| Peterson Kristine | Director Director | Nov 30 | Sell | 28.9 | 20,000 | 578,000 | 12/05/23 | |
| Peterson Kristine | Director Director | Nov 30 | Option | 11.59 | 20,000 | 231,800 | 20,000 | 12/05/23 |
| Wingrove Theresa | SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS | Nov 29 | Sell | 22.81 | 171,216 | 3,905,437 | 2,811 | 12/01/23 |
| Wingrove Theresa | SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS | Nov 29 | Option | 10.7 | 171,216 | 1,832,011 | 167,235 | 12/01/23 |
| Wingrove Theresa | SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS | Nov 15 | Sell | 15.85 | 166,725 | 2,642,591 | 2,811 | 11/17/23 |
| Wingrove Theresa | SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS | Nov 15 | Option | 4.55 | 166,725 | 758,599 | 169,536 | 11/17/23 |
| Coen Stacy Ann | SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER | Nov 15 | Sell | 16.02 | 108,609 | 1,739,916 | 36,966 | 11/17/23 |
| Coen Stacy Ann | SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER | Nov 15 | Option | 6.31 | 108,609 | 685,323 | 115,189 | 11/17/23 |
| Wingrove Theresa | SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS | Nov 07 | Sell | 16.66 | 19,517 | 325,153 | 2,811 | 11/08/23 |
| Wingrove Theresa | SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS | Nov 07 | Option | 10.65 | 19,517 | 207,856 | 22,328 | 11/08/23 |
| Lentini Renee | VP & PRIN ACCTG OFFI.. VP & PRIN ACCTG OFFICER | Nov 06 | Sell | 15.29 | 219,545 | 3,356,843 | 11/08/23 | |
| Lentini Renee | VP & PRIN ACCTG OFFI.. VP & PRIN ACCTG OFFICER | Nov 06 | Option | 7.05 | 120,528 | 849,722 | 219,545 | 11/08/23 |
| Wallace Richard John | Director Director | Nov 07 | Option | 14.70 | 10,000 | 147,000 | 10,000 | 11/08/23 |
| Goldberg Mark Alan | Director Director | Oct 30 | Option | 14.89 | 20,000 | 297,800 | 60,151 | 11/01/23 |
| Wingrove Theresa | SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS | Sep 15 | Sell | 15.44 | 192,013 | 2,964,681 | 2,811 | 09/19/23 |
| Wingrove Theresa | SVP OF REGULATORY AF.. SVP OF REGULATORY AFFAIRS | Sep 15 | Option | 3.43 | 108,668 | 372,731 | 194,824 | 09/19/23 |
| Peterson Kristine | Director Director | Sep 13 | Option | 15.39 | 20,000 | 307,800 | 09/14/23 | |
| MCCLUSKI STEPHEN C | Director Director | Sep 13 | Option | 15.38 | 20,000 | 307,600 | 09/14/23 | |
| Lentini Renee | PRIN. FIN & ACCTG... PRIN. FIN & ACCTG. OFF. | Sep 12 | Option | 4.28 | 25,141 | 107,603 | 99,017 | 09/14/23 |
| Coen Stacy Ann | SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER | Aug 09 | Sell | 14.2 | 100,210 | 1,422,982 | 10,960 | 08/11/23 |
| Coen Stacy Ann | SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER | Aug 09 | Option | 4.92 | 100,210 | 493,033 | 111,170 | 08/11/23 |
| Coen Stacy Ann | SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER | Aug 02 | Sell | 17.59 | 84,581 | 1,487,780 | 10,960 | 08/04/23 |
| Coen Stacy Ann | SVP & CHIEF BUSINESS.. SVP & CHIEF BUSINESS OFFICER | Aug 02 | Option | 4.92 | 84,581 | 416,139 | 91,286 | 08/04/23 |
| Enyedy Mark J | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Aug 02 | Sell | 17.29 | 3,007,554 | 52,000,609 | 553,270 | 08/04/23 |
| Enyedy Mark J | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Aug 02 | Option | 4.97 | 3,119,375 | 15,503,294 | 1,545,667 | 08/04/23 |
| Lentini Renee | PRIN. FIN & ACCTG... PRIN. FIN & ACCTG. OFF. | Aug 02 | Sell | 17.55 | 148,277 | 2,602,261 | 22,843 | 08/04/23 |
| Lentini Renee | PRIN. FIN & ACCTG... PRIN. FIN & ACCTG. OFF. | Aug 02 | Option | 3.98 | 199,310 | 793,254 | 73,876 | 08/04/23 |
| FOSTER DAVID G | V.P.-Fin., Prin. Acc.. V.P.-Fin., Prin. Acctg. Off. | Jan 04 | Sell | 6.38 | 11,052 | 70,512 | 37,912 | 01/04/21 |